RARE - Ultragenyx Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
69.72
+1.67 (+2.46%)
As of 11:36AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close68.05
Open67.59
Bid69.46 x 800
Ask69.65 x 800
Day's Range67.59 - 69.80
52 Week Range37.44 - 90.98
Volume90,499
Avg. Volume658,195
Market Cap3.982B
Beta (3Y Monthly)3.05
PE Ratio (TTM)N/A
EPS (TTM)-3.97
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est73.00
Trade prices are not sourced from all markets
  • Why Is Ultragenyx (RARE) Up 12.4% Since Last Earnings Report?
    Zacks2 hours ago

    Why Is Ultragenyx (RARE) Up 12.4% Since Last Earnings Report?

    Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

    Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RAREView full report here! Summary * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NegativeShort interest is moderately high for RARE with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 8. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold RARE had net inflows of $1.86 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire10 days ago

    Ultragenyx to Present at Upcoming Investor Conferences

    Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Cowen Annual Healthcare Conference on Tuesday, March 12, 2019 at 10 a.m. ET in Boston, MA. Tom Kassberg, the company’s Chief Business Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 at 8 a.m. ET in Miami, FL. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases.

  • GlobeNewswire23 days ago

    Ultragenyx Announces Pricing of Public Offering of Common Stock

    Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced the pricing of its underwritten public offering of 5,072,464 shares of its common stock at a price to the public of $60.00 per share resulting in gross proceeds of $304.3 million, before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 760,869 shares of the company's common stock at the public offering price, less the underwriting discount. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Merrill Lynch, and Cowen are acting as joint book-running managers for the offering.

  • GlobeNewswire24 days ago

    Ultragenyx Announces Proposed Public Offering of Common Stock

    Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it has commenced an underwritten public offering of up to $250,000,000 of shares of its common stock. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $37,500,000 of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.  J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Merrill Lynch and Cowen are acting as joint book-running managers for the offering.

  • Benzinga24 days ago

    Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

    Roche Holdings AG Basel ADR  (OTC: RHHBY )'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE ) has sparked a rally in the latter's shares. The Analysts ...

  • Investing.com24 days ago

    MarketPulse: Roche's Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks

    Investing.com – Swiss-based Roche Holding's bumper offer to acquire Spark Therapeutics on Monday propped up the healthcare sector and fueled speculation on Wall Street that more merger activity is in the pipeline for gene therapy stocks.

  • Thomson Reuters StreetEvents28 days ago

    Edited Transcript of RARE earnings conference call or presentation 19-Feb-19 10:00pm GMT

    Q4 2018 Ultragenyx Pharmaceutical Inc Earnings Call

  • GlobeNewswire28 days ago

    Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

    DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients Data from Higher-dose Cohort 2 Expected Mid-2019 NOVATO,.

  • GlobeNewswire28 days ago

    Report: Exploring Fundamental Drivers Behind Canopy Growth, Adobe, Ultragenyx Pharmaceutical, Humana, Ship Finance International, and NexGen Energy — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Here's Why This Small Biotech Stock Just Hit A Four-Month High
    Investor's Business Daily29 days ago

    Here's Why This Small Biotech Stock Just Hit A Four-Month High

    Ultragenyx Pharmaceutical stock jumped to a four-month high Wednesday on its strong launch for Crysvita, which treats a form of rickets. The firm is also working on other rare-disease drugs.

  • Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q4
    Zacks29 days ago

    Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q4

    Ultragenyx (RARE) loss narrower than expected and sales beat estimates in the fourth quarter of 2018.

  • Ultragenyx Pharmaceutical Inc (RARE) Q4 2018 Earnings Conference Call Transcript
    Motley Fool29 days ago

    Ultragenyx Pharmaceutical Inc (RARE) Q4 2018 Earnings Conference Call Transcript

    RARE earnings call for the period ending December 31, 2018.

  • Associated Presslast month

    Ultragenyx: 4Q Earnings Snapshot

    The Novato, California-based company said it had a loss of $1.73 per share. The results exceeded Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was ...

  • GlobeNewswirelast month

    Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update

    NOVATO, Calif., Feb. 19, 2019 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and.

  • ACCESSWIRElast month

    Ultragenyx Pharmaceutical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 19, 2019 / Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, ...

  • GlobeNewswirelast month

    Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)

    Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin Co. Ltd (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced positive results of a 64-week efficacy and safety analysis of the randomized active-controlled Phase 3 study of Crysvita® (burosumab) in children with X-linked hypophosphatemia (XLH) compared with oral phosphate and active vitamin D (current conventional therapy). The new results showed that Crysvita was superior to conventional therapy for all key efficacy endpoints, showing a meaningful improvement in rickets severity, lower limb deformity, growth, and physical functioning as demonstrated by increases in distance walked.

  • Will Ultragenyx (RARE) Report Negative Q4 Earnings? What You Should Know
    Zackslast month

    Will Ultragenyx (RARE) Report Negative Q4 Earnings? What You Should Know

    Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswirelast month

    Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update

    Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, February 19, 2019 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2018. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.

  • Is Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) Liquidity Good Enough?
    Simply Wall St.last month

    Is Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) Liquidity Good Enough?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Stocks with market capitalization between $2B and Read More...

  • GlobeNewswirelast month

    Ultragenyx Appoints Shehnaaz Suliman, M.D., to Board of Directors

    Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Shehnaaz Suliman, M.D., to the company’s Board of Directors, effective January 30, 2019. Dr. Suliman, Senior Vice President of Corporate Development and Strategy of Theravance Biopharma, Inc., will serve as an independent director to Ultragenyx. “Dr. Suliman joins the Ultragenyx Board at a key time for the company, and her corporate and commercial strategy experience will be a valuable asset as we continue to advance our pipeline and deliver therapies to patients with rare diseases in need of treatment options,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.

  • Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study
    Zacks2 months ago

    Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study

    Ultragenyx releases encouraging top-line data from the phase III study on UX007 in patients with LC-FAOD.

  • MarketWatch2 months ago

    Ultragenyx stock up 2.9% after safety and efficacy trial reaffirms Phase 2 data

    Shares of Ultragenyx Pharmaceutical Inc. rose 2.9% in premarket trade Tuesday after the company announced positive results from a safety and efficacy study looking at a treatment for patients with long-chain fatty acid oxidation disorder. Patients with this disorder are unable to properly break down fatty acids into energy, leading to serious liver, muscle and heart issues. Researchers looked at how Ultragenyx's drug, UX007, affected 75 patients, including 29 from a previous UX007 Phase 2 trial showing that UX007-treated patients had fewer illness-related visits to the hospital and fewer days in the hospital per year. The safety and efficacy study reaffirmed those results, also showing a reduction in the median number of hospital visits and days in the hospital per year among those treated with the drug. Ultragenyx said it is still on track to submit a new drug application for UX007 in mid-2019. Shares of Ultragenyx have gained 22.7% in the year to date through Friday, while the iShares Nasdaq Biotechnology ETF has gained 14.6%. The S&P 500 has gained 6.5%.